重组人类基因促红细胞生成素对早产儿视网膜病变影响的分析

目的　探讨重组人类基因促红细胞生成素（rhu-EPO）的应用对早产儿视网膜病变（ROP）的影响。方法 　对2005年3月至2008年6月期间收住福建医科大学附属漳州市医院新生儿科的早产儿（体重 ≤ 1500 g）病例资料进行分析,应用rhu-EPO治疗的94例为治疗组,未应用rhu-EPO的65例为对照组,生后6周或纠正胎龄35周时行眼底检查,根据ROP国际分期标准进行ROP诊断和分期,同时对多种相关因素进行统计分析。结果　治疗组严重ROP的患病率高于对照组（P < 0.05）;单因素分析显示rhu-EPO治疗 ≥ 10剂,发生严重ROP的风险高于rhu-EPO治疗剂数<10剂（r = 6.429,P < 0.001）,开始治疗时间 ≥ 14 d发生严重ROP风险明显高于 < 14 d（ r =46.000,P < 0.001）;多因素Logistic分析显示rhu-EPO治疗剂数 ≥ 10剂发生严重ROP风险高（r = 9.348,P < 0.001）。结论　应用rhu-EPO是早产儿ROP的一个独立危险因素。

Effect of the application of recombinant human erythropoietin on retinopathy of prematurity.

Objective　To evaluate the effect of the application of recombinant human erythropoietin （rhu-EPO） on retinopathy of prematurity（ROP）. Methods　All the clinical data of in-patient infants whose body weights were no more than 1500g during the period from March 2005 to June 2008 were reviewed. The group treated with rhu-EPO had 94 infants. Control group of 65 infants were not treated with rhu-EPO. Perform examination of fundus to the infants who were postnatal 6 weeks or whose correctal gestational ages were 35 weeks. Diagnosis and staging of ROP were established according to the international guidelines, and statistical analysis was done on several correlation factors at the same time. Results　Treatment group had higher incidence rate of serious ROP than control group （P < 0.05）.Analysis of single factor showed no-less-than 10 doses of rhu-EPO treatment had higher risk of serious ROP than less than 10 doses of rhu-EPO treatment （r = 6.429,P < 0.001）. The beginning therapy time no less than fourteen days had higher risk of serious ROP than that of less than fourteen days（r = 46.000,P < 0.001）. Logistic analysis of multiple factors displayed that no less than 10 doses of rhu-EPO treatment had higher risk of serious ROP（r = 9.348,P < 0.001）.Conclusion The application of recombinant Human Erythropoietin （rhu-EPO） is an independent risk factor of retinopathy of prematurity.